Phytochemicals of Hibiscus sabdariffa with Therapeutic Potential against SARS-CoV-2: A Molecular Docking Study

Öz

In this study, the possible interactions of 17 phytochemicals that were reported as the most abundant biomolecules of Hibiscus sabdariffa, including many organic acids as well as catechin and quercetin derivatives, with 3CLpro and PLpro proteases of SARS-CoV-2 have been investigated via molecular docking. Caffeoylshikimic acid/3CLpro showed the lowest binding energy (-7.72 kcal/mol) with seven H-bonds. The second-lowest binding energy was computed in the chlorogenic acid/3CLpro complex (-7.18 kcal/mol), which was found to form 6 H-bonds. Also, low binding energies of cianidanol (-7.10 kcal/mol), cryptochlorogenic acid (-6.67 kcal/mol), and kaempferol (-6.82 kcal/mol) were calculated to 3CLpro with several H-bond interactions. Nelfinavir (-10.16 kcal/mol) and remdesivir (-6.40 kcal/mol), which have been used against COVID-19, were obtained to have low binding energies to 3CLpro with 3 H-bond formations each. On the other hand, the nicotiflorin/PLpro complex, which had the lowest binding energy (-7.40 kcal/mol), was found to have only 1 H-bond interaction. The second-lowest binding energy was reported in chlorogenic acid/PLpro (-7.20 kcal/mol), which was found to possess four H-bonds. On the other hand, epigallocatechin gallate/PLpro, which was shown to have a -5.95 kcal/mol binding energy, was found to form 8 H-bond interactions. Furthermore, the quercetin pentosylhexoside/PLpro complex was monitored to have low binding energy (-6.54 kcal/mol) with 9 H-bonds, which stands as the highest number of H-bonds in all complexes. Therefore, several molecules of Hibiscus sabdariffa were found to have strong binding affinity to the main proteases of SARS-CoV-2. This study suggests many compounds, including caffeoylshikimic acid and nicotiflorin, to inhibit 3CLpro and PLpro activities. As a result, numerous chemicals derived from Hibiscus sabdariffa have the potential to be employed therapeutically against SARS-CoV-2 infection.

Anahtar Kelimeler

• 3CLpro
• Hibiscus sabdariffa
• molecular docking
• PLpro
• SARS-CoV-2

Kaynakça

1. Agrawal N, Goyal A, 2022. Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review. Current pharmaceutical biotechnology, 23(3): 396-419.
2. Al-Sehemi AG, Pannipara M, Parulekar RS, Kilbile JT, Choudhari PB, Shaikh MH, 2022. In silico exploration of binding potentials of anti SARS-CoV-1 phytochemicals against main protease of SARS-CoV-2. Journal of Saudi Chemical Society, 26(3): 101453.
3. Amin SA, Ghosh K, Singh S, Qureshi IA, Jha T, Gayen S, 2022. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery. Molecular diversity, 26(1): 215-228.
4. Arif MN, 2022. Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking Studies Unveil an Opportunity Against CORONA. Combinatorial chemistry & high throughput screening, 25(1): 197-203.
5. Cattaneo D, Cattaneo D, Gervasoni C, Corbellino M, Galli M, Riva A, Gervasoni C, Clementi E, Clementi E, 2020. Does lopinavir really inhibit SARS-CoV-2? Pharmacological research, 158: 104898.
6. Chen CC, Yu X, Kuo CJ, Min J, Chen S, Ma L, Liu K, Guo RT, 2021. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases. The FEBS journal, 288(17): 5089-5121.
7. Da-Costa-Rocha I, Bonnlaender B, Sievers H, Pischel I, Heinrich M, 2014. Hibiscus sabdariffa L. - a phytochemical and pharmacological review. Food chemistry, 165: 424-443.
8. Deb SD, Jha RK, Jha K, Tripathi PS, 2022. A multi model ensemble based deep convolution neural network structure for detection of COVID19. Biomedical signal processing and control, 71: 103126.

9. Derosa G, Maffioli P, D'Angelo A, Di Pierro F, 2021. A role for quercetin in coronavirus disease 2019 (COVID-19). Phytotherapy research : PTR, 35(3): 1230-1236.
10. Dong W, Wei X, Zhang F, Hao J, Huang F, Zhang C, Liang W, 2014. A dual character of flavonoids in influenza A virus replication and spread through modulating cell-autonomous immunity by MAPK signaling pathways. Scientific reports, 4: 7237.
11. Douangamath A, Fearon D, Gehrtz P, Krojer T, Lukacik P, Owen CD, Resnick E, Strain-Damerell C, Aimon A, Abranyi-Balogh P, Brandao-Neto J, Carbery A, Davison G, Dias A, Downes TD, Dunnett L, Fairhead M, Firth JD, Jones SP, Keeley A, Keseru GM, Klein HF, Martin MP, Noble MEM, O'Brien P, Powell A, Reddi RN, Skyner R, Snee M, Waring MJ, Wild C, London N, von Delft F, Walsh MA, 2020. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nature communications, 11(1): 5047.
12. Ghanbari R, Teimoori A, Sadeghi A, Mohamadkhani A, Rezasoltani S, Asadi E, Jouyban A, Sumner SC, 2020. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future microbiology, 15: 1747-1758.
13. Ghosh AK, Raghavaiah J, Shahabi D, Yadav M, Anson BJ, Lendy EK, Hattori SI, Higashi-Kuwata N, Mitsuya H, Mesecar AD, 2021. Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies. Journal of medicinal chemistry, 64(19): 14702-14714.
14. Gouhar SA, Elshahid ZA, 2021. Molecular docking and simulation studies of synthetic protease inhibitors against COVID-19: a computational study. Journal of biomolecular structure & dynamics: 1-21.
15. Hall DC, Jr., Ji HF, 2020. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel medicine and infectious disease, 35: 101646.
16. Hapsari BW, Manikharda, Setyaningsih W, 2021. Methodologies in the Analysis of Phenolic Compounds in Roselle (Hibiscus sabdariffa L.): Composition, Biological Activity, and Beneficial Effects on Human Health. Horticulturae, 7(2): 35.
17. Izquierdo-Vega JA, Arteaga-Badillo DA, Sanchez-Gutierrez M, Morales-Gonzalez JA, Vargas-Mendoza N, Gomez-Aldapa CA, Castro-Rosas J, Delgado-Olivares L, Madrigal-Bujaidar E, Madrigal-Santillan E, 2020. Organic Acids from Roselle (Hibiscus sabdariffa L.)-A Brief Review of Its Pharmacological Effects. Biomedicines, 8(5).
18. Jablonsky M, Steklac M, Majova V, Gall M, Matuska J, Pitonak M, Bucinsky L, 2022. Molecular docking and machine learning affinity prediction of compounds identified upon softwood bark extraction to the main protease of the SARS-CoV-2 virus. Biophysical chemistry, 288: 106854.
19. Kumar V, Roy K, 2020. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases. SAR and QSAR in environmental research, 31(7): 511-526.
20. McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C, 2020. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological research, 157: 104859.
21. Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert M, Fortin GM, Rayalam S, Taval S, 2021. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Communications biology, 4(1): 93.
22. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ, 2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry, 30(16): 2785-2791.
23. Mouffouk C, Mouffouk S, Mouffouk S, Hambaba L, Haba H, 2021. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL(pro) and PL(pro)), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2). European journal of pharmacology, 891: 173759.
24. Naik VR, Munikumar M, Ramakrishna U, Srujana M, Goudar G, Naresh P, Kumar BN, Hemalatha R, 2021. Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - in silico approach. Journal of biomolecular structure & dynamics, 39(13): 4701-4714.
25. Nguyen TT, Woo HJ, Kang HK, Nguyen VD, Kim YM, Kim DW, Ahn SA, Xia Y, Kim D, 2012. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnology letters, 34(5): 831-838.
26. Nouadi B, Ezaouine A, El Messal M, Blaghen M, Bennis F, Chegdani F, 2021. Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using Molecular Docking. Bioinformatics and biology insights, 15: 11779322211009199.
27. Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, Shirai T, Kanaya S, Ito Y, Kim KS, Nomura T, Suzuki T, Nishioka K, Ando S, Ejima K, Koizumi Y, Tanaka T, Aoki S, Kuramochi K, Suzuki T, Hashiguchi T, Maenaka K, Matano T, Muramatsu M, Saijo M, Aihara K, Iwami S, Takeda M, McKeating JA, Wakita T, 2021. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience, 24(4): 102367.
28. Omrani M, Keshavarz M, Nejad Ebrahimi S, Mehrabi M, McGaw LJ, Ali Abdalla M, Mehrbod P, 2020. Potential Natural Products Against Respiratory Viruses: A Perspective to Develop Anti-COVID-19 Medicines. Frontiers in pharmacology, 11: 586993.
29. Osipiuk J, Azizi SA, Dvorkin S, Endres M, Jedrzejczak R, Jones KA, Kang S, Kathayat RS, Kim Y, Lisnyak VG, Maki SL, Nicolaescu V, Taylor CA, Tesar C, Zhang YA, Zhou Z, Randall G, Michalska K, Snyder SA, Dickinson BC, Joachimiak A, 2021. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nature communications, 12(1): 743.
30. Parga-Lozano C, 2020. Hibiscus Sabdariffa como candidato terapéutico para COVID-19. Duazary, 17(4): 1-3.
31. Shawky E, Nada AA, Ibrahim RS, 2020. Potential role of medicinal plants and their constituents in the mitigation of SARS-CoV-2: identifying related therapeutic targets using network pharmacology and molecular docking analyses. RSC Advances, 10(47): 27961-27983.
32. Singh G, Pawan, Mohit, Diksha, Suman, Priyanka, Sushma, Saini A, Kaur A, 2022. Design of new bis-triazolyl structure for identification of inhibitory activity on COVID-19 main protease by molecular docking approach. Journal of molecular structure, 1250: 131858.
33. Solnier J, Fladerer JP, 2021. Flavonoids: A complementary approach to conventional therapy of COVID-19? Phytochemistry reviews : proceedings of the Phytochemical Society of Europe, 20(4): 773-795.
34. Steklac M, Zajacek D, Bucinsky L, 2021. 3CL(pro) and PL(pro) affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found? Journal of molecular structure, 1245: 130968.
35. Takeuchi Y, Akashi Y, Kato D, Kuwahara M, Muramatsu S, Ueda A, Notake S, Nakamura K, Ishikawa H, Suzuki H, 2021. The evaluation of a newly developed antigen test (QuickNavi-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 27(6): 890-894.
36. Tomani JCD, Kagisha V, Tchinda AT, Jansen O, Ledoux A, Vanhamme L, Frederich M, Muganga R, Souopgui J, 2020. The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials. Molecules, 25(20).
37. Vlachakis D, Papakonstantinou E, Mitsis T, Pierouli K, Diakou I, Chrousos G, Bacopoulou F, 2020. Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 146: 111805.
38. WHO, 2022. COVID-19 Therapeutics under Assessment.
39. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, Li H, 2020. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta pharmaceutica Sinica. B, 10(5): 766-788.